Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Spravato is just the beginning in a new wave of depression meds

Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

J&J wins FDA approval for Varipulse PFA system

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners